Breaking News Instant updates and real-time market news.

NKTR

Nektar

$17.21

0.4 (2.38%)

12:45
10/11/16
10/11
12:45
10/11/16
12:45

Nektar has a conference call hosted by JPMorgan

JPMorgan Analysts Kasimov, Fye and Rama will host a conference call with Steve Doberstein, CSO, and Johnathan Zalevsky, VP of Biology on October 11 at 1 pm.

  • 11

    Oct

  • 14

    Dec

NKTR Nektar
$17.21

0.4 (2.38%)

09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
09/30/16
BMUR
09/30/16
INITIATION
Target $23
BMUR
Buy
Nektar assumed with a Buy at Brean Capital
Brean Capital analyst Difei Yang assumed coverage of Nektar Therapeutics with a Buy rating and raised her price target for the shares to $23 from $18. The company has built an "extensive pipeline" from licensing and partnership deals, Yang tells investors in a research note.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
08/04/16
BMUR
08/04/16
NO CHANGE
Target $18
BMUR
Buy
Nektar has promising pipeline, says Brean Capital
Brean Capital raised its price target on Nektar Therapeutics to $18 from $16 citing the company's successful launch of Movantik and other drugs as well as the promise of its pipeline of drugs. Brean Capital reiterated its Buy rating on Nektar shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.